» Lunatus News
» Lunatus partners with NantHealth to bring GPS Cancer™ to oncologists & patients in the Middle East
Lunatus partners with NantHealth to bring GPS Cancer™ to oncologists & patients in the Middle East
Lunatus has entered into an exclusive reseller agreement with NantHealth, a leading next-generation, evidence-based, personalized healthcare company, for GPS Cancer Advanced Molecular Analysis. The molecular tests will help guide the decisions made by oncologists located in the Middle East regarding a patient’s treatment strategy, including choice of standard chemotherapy.
- Oncologists in United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon will be empowered to make more informed clinical decisions to personalize treatment and care for their patients
- Partnership builds on international expansion of GPS Cancer which was recently made available in Italy
Click here to read the full Press Release